Sulforaphane improves cognitive function administered following traumatic brain injury. by Dash, Pramod K et al.
SULFORAPHANE IMPROVES COGNITIVE FUNCTION
ADMINISTERED FOLLOWING TRAUMATIC BRAIN INJURY
Pramod K. Dash*, Jing Zhao, Sara A. Orsi, Min Zhang, and Anthony N. Moore
Department of Neurobiology and Anatomy, The University of Texas Medical School, Houston, Texas
77225
Abstract
Recent studies have shown that sulforaphane, a naturally occurring compound that is found in
cruciferous vegetables, offers cellular protection in several models of brain injury. When
administered following traumatic brain injury (TBI), sulforaphane has been demonstrated to
attenuate blood-brain barrier permeability and reduce cerebral edema. These beneficial effects of
sulforaphane have been shown to involve induction of a group of cytoprotective, Nrf2-driven genes,
whose protein products include free radical scavenging and detoxifying enzymes. However, the
influence of sulforaphane on post-injury cognitive deficits has not been examined. In this study, we
examined if sulforaphane, when administered following cortical impact injury, can improve the
performance of rats tested in hippocampal- and prefrontal cortex-dependent tasks. Our results
indicate that sulforaphane treatment improves performance in the Morris water maze task (as
indicated by decreased latencies during learning and platform localization during a probe trial) and
reduces working memory dysfunction (tested using the delayed match-to-place task). These
behavioral improvements were only observed when the treatment was initiated 1 hr, but not 6 hr,
post-injury. These studies support the use of sulforaphane in the treatment of TBI, and extend the
previously observed protective effects to include enhanced cognition.
Keywords
TBI; Nrf2; prefrontal cortex; hippocampus; spatial memory
Introduction
Cells possess endogenous protective mechanism(s) as a defense against environmental insults
and injury. These cellular defenses often involve induction of cytoprotective genes whose
protein products scavenge and/or neutralize toxins. A few regulatory pathways have been
identified involving specific transcription factors that induce the expression of cytoprotective
proteins and enzymes [11]. The transcription factor Nrf2 (nuclear factor E2-related factor 2)
binds to the antioxidant/electrophilic response element (ARE/EpRE) and regulates the
expression of multiple cytoprotective proteins including antioxidant and glutathione generating
enzymes [8;15]. Nrf2 is normally sequestered in the cytoplasm through its interaction with
KEAP1 where it is rapidly turned-over by the ubiquitin-proteosome system [9;16]. The
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naturally occurring compound sulforaphane, which is present in cruciferous vegetables such
as broccoli, has been shown to reduce the proteosomal degradation of Nrf2, resulting in its
nuclear accumulation and increased expression of Nrf2-driven genes [16].
Our previous studies have shown that systemic administration of sulforaphane results in
increased expression of Nrf2-driven genes in rodent brains and microvasculature [17;18].
Consistent with this, post-injury administration of this compound to rodents with traumatic
brain injury (TBI) attenuates blood-brain barrier permeability and reduces brain edema [17;
18]. In the present study, we investigated if post-injury sulforaphane administration improves
cognitive function. Our results indicate that sulforaphane administration initiated at 1 hr, but




Male Sprague Dawley rats (300 g) were purchased from Harlan (Indianapolis, IN).
Sulforaphane (Catalog No. S8044) was purchased from LKT Laboratories, Inc. (St. Paul, MN).
Anti-4-Hydroxy-2-noneal (4-HNE) antibody was purchased from EMD Chemicals, Inc.
(Gibbstown, NJ).
Controlled cortical impact injury and drug administration
All experimental procedures were approved by the Institutional Animal Care and Use
Committee and conducted in accordance with the recommendations provided in the Guide for
the Care and Use of Laboratory Animals. A controlled cortical impact (CCI) device was used
to cause brain injury as previously described [3]. Bilateral craniectomies were positioned
midway between the bregma and lambda and animals received a single impact (2.7 mm
deformation, 6 meters/sec) on the right parietal lobe. Sulforaphane was dissolved in corn oil
and administered by intraperitoneal (i.p.) injection.
Assessment of cognitive function
Spatial memory was tested using the standard hidden platform version of the Morris water
maze task (MWM) (beginning on day 14 post-injury) followed by a working memory task
(beginning on day 25 post-injury). Animals were randomly assigned to either drug or vehicle
groups. For the MWM task, animals were trained for 7 consecutive days and were given 4
training trials (60 seconds maximum) per day, with an inter-trial interval (iti) of 4min [2;5]. If
the animal failed to locate the platform within 60sec on any given trial, it was led there by the
experimenter where it was allowed to rest for 30sec. If no significant differences were detected
during the first 5 days, training was discontinued. Twenty-four hours following the last day of
training, animals were tested for retention by administering a 60sec probe trial. Movement
within the maze was monitored using a video camera linked to tracking software (Ethovision,
Noldus Information Technology, Leesbury, VA, USA). The time to cross the site at which the
platform was located during training, the number of platform crossings, and quadrant
preference was calculated.
Following MWM training and testing, animals were tested in a delayed match-to-place spatial
working memory task [6]. For each testing pair of trials, animals were given a location trial,
in which the platform and start location were randomized. Animals were then allowed to search
for the platform for a period of 60sec (location trial) and once found, the animal was allowed
to rest on it for 10sec. The animal was removed from the water maze and after a 5sec delay,
allowed to once again search for the hidden platform (match trial). This procedure of location
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and match trial was repeated 5 times (each pair separated by a 4min iti) with the platform in a
novel location for each pair.
Immunohistochemistry
Sulforaphane (5mg/kg) or vehicle was injected i.p. 1 hr and 24hr after injury. One hour
following the last injection, animals were deeply anesthetized with sodium pentobarbital
(100mg/kg) and transcardially perfused with PBS followed by 4% paraformaldehyde. Brains
were removed, and coronal sections prepared on a cryostat. Sections were incubated with
primary antibodies (anti-4-HNE or anti-NeuN) in 2.5% goat serum in Tris buffered saline
containing 0.1% triton X-100 for 48hr at 4°C. Immunoreactivity was detected by species-
specific secondary antibodies conjugated to Alexafluors. Photomicrographs (2 sections/
animal) were taken of the cortex and the dorsal hippocampus for quantification of 4-HNE
immunoreactivity. Camera settings remained constant for all animals. NeuN immunoreactivity
was used to define hippocampal subfields. Immunoreactivity was assessed using Image J
(available from NIH) and calculated as optical density/mm2.
Statistical Analysis
For evaluation of behavioral data, a two-way repeated measures analysis of variance was
utilized to determine group differences. A Holm-Sidak method for multiple comparisons was
used to determine data points with significant differences. Optical density measurements for
immunohistochemistry were evaluated using a Student’s t-test for unpaired variables. Data
were considered significant at p < 0.05 and presented as Mean ± Standard Error of the Mean
(S.E.M.).
Results
Early, but not delayed, sulforaphane administration following injury significantly improves
spatial memory
We have previous demonstrated that sulforaphane given 6hr post-injury significantly reduces
post-TBI blood-brain barrier permeability and cerebral edema [17;18]. To test if this
administration routine is associated with a cognitive improvement, rats were injured and
injected with either sulforaphane (5mg/kg) or vehicle 6hr post-injury (n=10/group) (Figure
1A). Beginning on day 14 post-injury, animals were tested in the standard hidden platform
version of the Morris water maze. Figure 1A shows that there was no significant difference in
water maze performance between the sulforaphane- and vehicle-treated animals when the
compound was administered 6hr post-injury (group main comparison: F(1,9)=0.495, p=0.499).
To prolong the effectiveness of the drug, injured animals (n=10/group) were given a dose of
sulforaphane (5 mg/kg) or vehicle at 6hr post-injury, followed by a second injection at 24hr
post-injury. Figure 1B shows that the addition of a second sulforaphane injection also had no
significant effect on water maze performance (group main comparison: F(1,9)=0.603, p=0.457).
In contrast, when the drug was administered earlier, injured animals receiving sulforaphane
(n=9) at 1hr and 24hr post-injury performed significantly better than their vehicle-treated
counterparts (n=10) (group main effect: F(1,8)=6.750, p=0.032). As these rats had significantly
improved performance after 5 of training, they were given an additional 2 days of training to
ensure that the differences in learning would be maintained (Figure 1C; group main effect:
F(1,8)=10.270, p=0.013). These differences in performance were not due to changes in
swimming speed (swimming speed at end of training: vehicle, 28.10 ± 1.04 cm/sec;
sulforaphane, 30.42 ± 1.90 cm/sec, n.s.)
To determine if the improved performance in the 1hr and 24hr sulforaphane-treated animals
was associated with measures of platform localization, a probe test was given 24hr following
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the completion of training. The representative traces shown in figure 2A demonstrate the initial
swimming paths taken by a vehicle- and sulforaphane–treated animal during the probe trial
(Figure 2A). When analyzed for quadrant dwell times, a significant preference for the target
quadrant (I) (quadrant that contained the hidden platform) was found for the sulforaphane-
treated animals (Figure 2B). In contrast, the vehicle infused animals only had a significant
difference in dwell time between the target quadrant (I) and the start quadrant (III). The probe
test was further analyzed for localization differences between the groups by determining the
latencies to, and number of times the animals entered, concentric rings of decreasing diameter
centered on the platform location. The summary graph shown in figure 2C shows that while
the sulforaphane-treated animals proceed from the outermost ring (4×) to the platform with
minimal delay, the vehicle-injected animals had significantly longer latencies to reach the inner
rings (+, interaction between group and latency: F(3,48)=2.949, p=0.042). Consistent with this,
the sulforaphane-injected animals were found to cross the site of the platform location
significantly more often than the vehicle-injected animals (vehicle, 1.00 ± 0.33 crossings;
sulforaphane, 2.33 ± 0.44 crossings, p=0.028; Figure 2D). These measures of platform
localization were not detected in animals injected with sulforaphane at either 6hr, or 6hr and
24hr, post-injury.
Sulforaphane administration following injury improves spatial working memory
Beginning on day 25 post-injury, the animals treated at 1hr and 24 hr post-injury were further
tested using the delayed match-to-place working memory task (Figure 3A). Figure 3B shows
representative traces from vehicle- and sulforaphane-treated rats during the location and match
trials. Vehicle-injected animals did not show any significant decline in latency between the
location and match trials (location trial: 36.08 ± 5.25 sec; match trial: 39.24 ± 9.63 sec;
p=0.110), indicating impaired working memory. In contrast, animals receiving sulforaphane
reached the platform during the match trial significantly faster than during the location trial
(location trial: 41.18 ± 2.48 sec; match trial: 25.94 ± 2.48 sec; p=0.001). Comparison of the
two groups revealed a significant interaction between group and trial (F(1,8)=15.669, p=0.004).
Systemic administration of sulforaphane attenuates TBI-associated oxidative damage in the
brain
Since a number of Nrf2-driven genes have antioxidant functions, we examined if the cognitive
improvement observed following sulforaphane administration was associated with reduced
oxidative damage in the brains of TBI animals. Animals were injured (n=4/group) and at 1hr
and 24hr post-injury, treated with either 5mg/kg sulforaphane or vehicle. One hour after the
last injection, brains were removed for immunological evaluation of 4-Hydroxynonenal (4-
HNE), a marker of lipid peroxidation [4]. Sections were double-labeled with anti-NeuN to
identify neuronal layers. Figure 4 shows representative images of the cerebral cortex
immediately adjacent to the injury core (Figure 4A) and dorsal hippocampus (Figure 4B) from
a TBI animal treated with vehicle and a TBI animal treated with 5 mg/kg sulforaphane. As the
immunoreactivity for 4-HNE appeared primarily in the CA3 (an area highly vulnerable to TBI)
and dentate gyrus subfields of the hippocampus in vehicle-treated animals, these areas were
chosen for quantification. Figure 4C shows that 4-HNE immunoreactivity (calculated as optical
density/mm2) was significantly reduced in the cortex of sulforaphane-treated animals
(Student’s t-test: p=0.0006). Likewise, 4-HNE immunoreactivity was found to be significantly
reduced in the CA3 subfield of the hippocampus (Student’s t-test: p=0.035). No significant
difference was found in the dentate gyrus (Student’s t-test: p=0.220), presumably due to the
high degree of variability detected in the vehicle-treated animals (Figure 4D).
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To defend against exogenous toxins and harmful products of cellular respiration, cells contain
a large number of antioxidant and detoxifying enzymes whose expressions are rapidly
increased in response to threats. Many of these genes contain binding sites for the transcription
factor Nrf2 and can therefore be regulated by the Nrf2-activating compound sulforaphane [8;
15]. Our laboratory has previously shown that post-injury administration of sulforaphane
reduces TBI-associated blood-brain barrier permeability and attenuates cerebral edema [17;
18]. In the present study, we extend these findings to show that sulforaphane, when given to
rats following cortical impact injury, improves hippocampal- and prefrontal cortex-dependent
cognitive functions. These preclinical findings further support the use of sulforaphane as a
potential treatment option following brain injury.
Increased generation of reactive oxygen or nitrogen species, such as superoxide, hydroxyl
radicals, and peroxynitrite are widely recognized as important contributors to the pathology of
brain trauma. Because of this, several studies have evaluated the protective effects of free
radical scavenging compounds, altered expression of detoxifying enzymes, and other
neuroprotective agents as putative treatments for TBI [10;12;13]. For example, overexpression
of Cu/Zn superoxide dismutase was found to decrease blood-brain barrier permeability,
cerebral edema, and motor dysfunction in a dose-dependent manner following a weight-drop
model of brain injury. Sulforaphane, a naturally occurring compound generated from
cruciferous vegetables such as broccoli, is a potent inducer of antioxidant and detoxifying
enzymes [15]. As such, this compound has been suggested to provide broad protection against
a variety of cellular threats. For example, application of sulforaphane to neuron-astrocyte co-
cultures protects neurons against nonexcitotoxic glutamate and hydrogen peroxide toxicity
[7]. Consistent with this ability of sulforaphane to reduce oxidative damage, we observed that
sulforaphane administered 1hr and 24hr post-injury significantly reduced 4-HNE
immunoreactivity in the CA3 subfield of the hippocampus and the cortex surrounding the injury
site. The CA3 subfield has been demonstrated to be vulnerable to lateral cortical impact injury,
and damage to this area is thought to contribute to hippocampal-dependent learning and
memory dysfunction [1].
We have previously demonstrated that a single, post-injury injection of sulforaphane is
sufficient to stimulate the expression of Nrf2-dependent genes and reduce TBI-associated
blood-brain barrier permeability and cerebral edema [17;18]. While encouraging, the
consequences of sulforaphane on post-injury cognition were not tested. In this study, we present
data to demonstrate that in addition to vascular protection, post-injury sulforaphane treatment
preserves neurologic function in injured animals. This improvement was evidenced by
enhanced learning and memory, and by improved performance in a working memory task.
Although the systemic nature of the drug treatment paradigm employed in this study prevents
ascribing these neurologic improvements to a specific brain structure, both the Morris water
maze task and the delayed match-to-place task are dependent on the hippocampus, suggesting
a preservation of this structure’s function. However, working memory is heavily dependent on
the transient storage and manipulation of information by the prefrontal cortex. Thus, the
improved performance observed in the delayed match-to-place task may also reflect a reduction
of prefrontal cortex dysfunction. Future studies using targeted infusions of sulforaphane may
be required to determine the contribution of individual structures to the effects we observed.
Based on our previous observations that sulforaphane could offer protection against blood-
brain barrier compromise when delayed by as much as 6 hr post-injury [17;18], and the premise
that the components of the neurovascular unit (a functional unit composed of neurons,
astrocytes, oligodendrocytes and brain endothelial cells) work in concert to maintain brain
function, we anticipated that cognitive improvement would be seen when sulforaphane was
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administered 6hr post-injury. However, hippocampal-dependent behavioral improvements
were only observed when sulforaphane treatment was initiated within 1 hr of injury. The reason
for the dissociation between vascular protection and cognitive improvement is not clear at
present. As a number of factors are required for improvement of cognitive function, simply
improving vascular permeability may not be sufficient. Furthermore, although oxidative
damage may occur in the neurons and endothelial cells with similar time courses [4], there is
evidence to suggest that neurons may be particularly sensitive to injury. For example, using
the expression of hsp70 as a marker of injury, it has been shown that brief periods of ischemia
results in hsp70 induction first in neurons, followed by glia, and finally in endothelial cells
[14]. Therefore, sufficient oxidative damage may have occurred within neurons by 6hr post-
injury to make this delay incapable of improving cognitive function. Regardless of the
underlying reasons for the observed differences in time windows, our results on the behavioral
and pathophysiological improvements offered by post-injury sulforaphane administration
suggest that this compound is a promising therapeutic option for the treatment of brain injury
patients.
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Figure 1. Post-injury administration of sulforaphane improves water maze performance
Performance in the Morris water maze task was tested 14 days after injury. Sulforaphane (5
mg/kg) or vehicle was administered by i.p. injection at either A) 6 hr, B) 6hr and 24hr, or C)
1hr and 24hr post-injury. ↓, time of injection. MWM: Morris water maze. DMTP: delayed
match-to-place task. +, significant group main effect. *, p <0.05 between vehicle and
sulforaphane groups.
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Figure 2. Improved water maze performance is associated with enhanced measures of spatial
localization
Twenty-four hours following the completion of training, rats were tested in a probe trial. A)
Representative probe traces of swimming paths for a sulforaphane and a vehicle injected
animal. The trace shows the path taken from the time of maze entry to the first crossing of the
platform location. B) Quantification of time spent in each quadrant of the water maze during
the probe trial. *, significant differences in dwell time. C) The latency to enter concentric circles
(4X, 3X, 2X or 1X the diameter of the platform) centered on the platform (+, significant group
main effect). D) Platform crossings during the probe trial. Data are represented as mean ± SEM.
*, p <0.05 between vehicle and sulforaphane groups.
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Figure 3. Post-injury administration of sulforaphane improves working memory. A)
Schematic diagram showing the protocol of delayed match-to-place testing consisting of
location (Loc) and match trials, separated by a 5 sec delay. Five pairs of location and match
trials were performed, with the platform position in a novel site for each pair. Each pair of trials
was separated by a 4 min inter-trial interval. B) Representative traces of a vehicle and a
sulforaphane (Sul)-treated animal during the location and match trials. C) Summary data
showing average latencies to the platform during the location and match trials. +, significant
interaction between trial number and treatment groups; *, p<0.05 between location and match
trials. Data are represented as mean ± SEM.
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Figure 4. Post-injury administration of sulforaphane decreases oxidative damage in the brain
Representative images showing the relative immunoreactivity of 4-HNE in an injured animal
receiving vehicle, and an injured animal receiving 5mg/kg sulforaphane 1hr and 24hr post-
injury. Images were taken from the A) cerebral cortex immediately adjacent to the injury
location, and B) the ipsilateral hippocampus. Hippocampal subfields were identified by NeuN
double-label immunohistochemistry and indicated by gray lines. Summary date for
quantification of 4-HNE immunoreactivity from C) the ipsilateral cortex adjacent to the site
of injury, D) the CA3 subfield, and D) the dentate gyrus. *, P <0.05. Veh: vehicle; Sul:
sulforaphane; DG: dentate gyrus
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